Literature DB >> 25687157

Autophagy is involved in the initiation and progression of Graves' orbitopathy.

Jin Sook Yoon1, Hyun Jung Lee, Min Kyung Chae, Eun Jig Lee.   

Abstract

BACKGROUND: Differentiation of orbital fibroblasts into mature adipocytes and subsequent accumulation of adipose tissue has been shown in the progression of Graves' orbitopathy (GO). Autophagy is involved in adipogenesis, but little is known about the role of autophagy in the initiation and progression of GO. The aim of this study is to investigate the role of autophagy in the pathogenesis of GO.
METHODS: Orbital adipose/connective tissue explants from patients with GO and from normal subjects, as well as isolated orbital fibroblasts, were analyzed. Adipogenesis was induced using differentiating medium with or without hydrogen peroxide, and autophagy was manipulated using bafilomycin A1 and Atg5-targeted short hairpin RNA (shRNA). Autophagosomes were identified by electron microscopy. Expression of autophagy-related genes and adipogenesis-related transcription factors were analyzed by real time reverse transcription-polymerase chain reaction and/or Western blot analysis. Lipid droplet accumulation was examined by Oil Red O staining.
RESULTS: Autophagic vacuoles were more abundant in GO cells than in non-GO cells (p<0.05). Expression of autophagy-related genes was significantly higher in GO tissues and cells than in their non-GO counterparts, respectively. Interleukin-1β increased LC3-II, p62, and Atg7 protein in GO cells. Autophagosome accumulation was shown at day 4 of adipogenesis and decreased by day 10, along with lipid droplet formation. Expression of LC3 and p62 proteins increased within 48 hours of differentiation and diminished gradually from day 4 to 10. Bafilomycin A1 treatment and Atg5 knockdown by shRNA inhibited lipid droplet accumulation and suppressed expression of adipogenic markers.
CONCLUSIONS: Autophagy was increased in GO tissue and cells compared to non-GO tissue and cells, suggesting that autophagy plays a role in GO pathogenesis. Autophagy manipulation may be a therapeutic target for GO.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25687157     DOI: 10.1089/thy.2014.0300

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  12 in total

1.  Statin reduces orbitopathy risk in patients with Graves' disease by modulating apoptosis and autophagy activities.

Authors:  Maurizio Bifulco; Elena Ciaglia
Journal:  Endocrine       Date:  2015-10-05       Impact factor: 3.633

2.  Interferon-α Triggers Autoimmune Thyroid Diseases via Lysosomal-Dependent Degradation of Thyroglobulin.

Authors:  Larissa C Faustino; Angela Lombardi; Julio Madrigal-Matute; Randall P Owen; Steven K Libutti; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2018-10-01       Impact factor: 5.958

3.  Astragaloside IV attenuates orbital inflammation in Graves' orbitopathy through suppression of autophagy.

Authors:  Hong Li; Yali Zhang; Jie Min; Long Gao; Ren Zhang; Yucheng Yang
Journal:  Inflamm Res       Date:  2017-11-10       Impact factor: 4.575

Review 4.  The Evolving Functions of Autophagy in Ocular Health: A Double-edged Sword.

Authors:  Peiwei Chai; Hongyan Ni; He Zhang; Xianqun Fan
Journal:  Int J Biol Sci       Date:  2016-10-25       Impact factor: 6.580

5.  Pingmu Decoction Induces Orbital Preadipocytes Apoptosis In Vitro.

Authors:  Yali Zhang; Hong Li; Long Gao; Xia Zhang; RuiFang Xie
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-18       Impact factor: 2.629

6.  Icariin Inhibits AMPK-Dependent Autophagy and Adipogenesis in Adipocytes In vitro and in a Model of Graves' Orbitopathy In vivo.

Authors:  Hong Li; Yifei Yuan; Yali Zhang; Xia Zhang; Long Gao; Rongjuan Xu
Journal:  Front Physiol       Date:  2017-02-13       Impact factor: 4.566

Review 7.  Cholesterol Serum Levels and Use of Statins in Graves' Orbitopathy: A New Starting Point for the Therapy.

Authors:  Giulia Lanzolla; Guia Vannucchi; Ilaria Ionni; Irene Campi; Federica Sileo; Elisa Lazzaroni; Michele Marinò
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-22       Impact factor: 5.555

8.  Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves' Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways.

Authors:  Yi-Hsuan Wei; Shu-Lang Liao; Sen-Hsu Wang; Chia-Chun Wang; Chang-Hao Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-02-01       Impact factor: 5.555

9.  Identification of New Rare Variants Associated With Familial Autoimmune Thyroid Diseases by Deep Sequencing of Linked Loci.

Authors:  Cheuk Wun Li; Ravi Sachidanandam; Anitha Jayaprakash; Zhengzi Yi; Weijia Zhang; Mihaela Stefan-Lifshitz; Erlinda Concepcion; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

10.  Novel Roles of Chloroquine and Hydroxychloroquine in Graves' Orbitopathy Therapy by Targeting Orbital Fibroblasts.

Authors:  Yan Guo; Hai Li; Xueying Chen; Huasheng Yang; Hongyu Guan; Xiaoying He; Yuxin Chen; Sunil Pokharel; Haipeng Xiao; Yanbing Li
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.